Recursion Pharmaceuticals, Inc.
RXRX
$3.05
-$0.10-3.18%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 6.47M | 35.54M | 5.18M | 19.22M | 14.75M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.47M | 35.54M | 5.18M | 19.22M | 14.75M |
| Cost of Revenue | 100.39M | 110.22M | 135.75M | 148.80M | 151.46M |
| Gross Profit | -93.91M | -74.68M | -130.57M | -129.57M | -136.72M |
| SG&A Expenses | 34.59M | 42.17M | 41.63M | 46.65M | 54.65M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 134.98M | 152.39M | 177.38M | 195.45M | 206.11M |
| Operating Income | -128.51M | -116.85M | -172.20M | -176.23M | -191.37M |
| Income Before Tax | -122.11M | -108.10M | -162.25M | -171.90M | -202.65M |
| Income Tax Expenses | -4.60M | 20.00K | 3.00K | -- | -158.00K |
| Earnings from Continuing Operations | -117.50M | -108.12M | -162.25M | -171.90M | -202.49M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -117.50M | -108.12M | -162.25M | -171.90M | -202.49M |
| EBIT | -128.51M | -116.85M | -172.20M | -176.23M | -191.37M |
| EBITDA | -108.83M | -97.37M | -151.16M | -152.38M | -172.04M |
| EPS Basic | -0.22 | -0.21 | -0.36 | -0.41 | -0.50 |
| Normalized Basic EPS | -0.14 | -0.14 | -0.23 | -0.26 | -0.31 |
| EPS Diluted | -0.22 | -0.21 | -0.36 | -0.41 | -0.50 |
| Normalized Diluted EPS | -0.14 | -0.14 | -0.23 | -0.26 | -0.31 |
| Average Basic Shares Outstanding | 529.30M | 526.72M | 446.99M | 417.36M | 402.77M |
| Average Diluted Shares Outstanding | 529.30M | 526.72M | 446.99M | 417.36M | 402.77M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |